Feasibility of safe ultra-high (EQD₂>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy

References

• Djavan B, Milani S, Remzi M. Prostate biopsy: Who, how and when. An update. Can J Urol 2005;12(Suppl 1):44–8.
   PubMedGoogle Scholar
• Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, Briganti A, . Unilateral prostate cancer cannot be accurately predicted in low-risk patients. Int J Radiat Oncol Biol Phys 2010;77:784–7.
   PubMedGoogle Scholar
• Viani GA, Stefano EJ, Afonso SL. Higher than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405–18.
   PubMed Web of Science ®Google Scholar
• Cellini N, Morganti AG, Matteucci GC, Valentini V, Leone M, Luzi S, . Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002;53:595–9.
   PubMed Web of Science ®Google Scholar
• Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, . Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007;69:62–9.
   PubMed Web of Science ®Google Scholar
• Kim Y, Tomè WA. Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of entire tumor based on equivalent EUD plans. Acta Oncol 2008;47:906–16.
   PubMed Web of Science ®Google Scholar
• Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, . Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750–7.
   PubMed Web of Science ®Google Scholar
• Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, . Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417–28.
   PubMed Web of Science ®Google Scholar
• Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W, . Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur J Radiol 2010 (in press).
   Google Scholar
• Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, . Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: Preliminary findings. Urology 2002;60:634–9.
   PubMed Web of Science ®Google Scholar
• Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, . Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9:342–51.
   PubMed Web of Science ®Google Scholar
• Van Lin ENJT, Futterer JJ, Heijmink SWTPJ, Van Der Vight LP, Hoffmann AL, Van Kollenburg P, . IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65:291–303.
   PubMed Web of Science ®Google Scholar
• Moman MR, Van Den Berg CAT, Boeken Kruger AE, Battermann JJ, Moerland MA, Van Der Heide UA, . Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 2010;76:741–6.
   PubMedGoogle Scholar
• Haider MA, Van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, . Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189:323–8.
   PubMed Web of Science ®Google Scholar
• Kajihara H, Hayashida Y, Murakami R, Katahira K, Nishimara R, Hamada Y, . Usefulness of diffusion-weighted imaging in the localization of prostate cancer. Int J Radiat Oncol Biol Phys 2009;74:399–403.
   PubMed Web of Science ®Google Scholar
• Groenendaal G, van den Berg CAT, Korporaal JG, Philippens MEP, Luijten PR, van Vulpen M, . Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010;95:185–90.
   PubMed Web of Science ®Google Scholar
• Kim CK, Park BK, Han JJ, Kang TW, Lee HM. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: Preliminary results. J Comput Assist Tomogr 2007;31:449–54.
   PubMedGoogle Scholar
• Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, . Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zone of the prostate. J Magn Reson Imaging 2005;21:258–62.
   PubMed Web of Science ®Google Scholar
• Kumar V, Jagannathan NR, Kumar R, Das SC, Jindal L, Thulkar S, . Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006;24:541–8.
   PubMedGoogle Scholar
• Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 2000;48:593–9.
   PubMed Web of Science ®Google Scholar
• Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 2002;54:921–7.
   PubMed Web of Science ®Google Scholar
• Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD, . Incorporating clinical measurements of hypoxia into tumor local control modelling of prostate cancer: Implications for the α/β ratio. Int J Radiat Oncol Biol Phys 2003;57: 391–401.
   PubMed Web of Science ®Google Scholar
• Niyazi M, Bartenstein P, Belka C, Ganswindt U. Choline PET based dose-painting in prostate cancer – Modelling of dose effects. Radiat Oncol 2010;5:23.
   PubMed Web of Science ®Google Scholar
• Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Casanova Borca V, . Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 2004;73:21–32.
   PubMed Web of Science ®Google Scholar
• Rancati T, Fiorino C, Vavassori V, Baccolini M, Bianchi C, Foppiano F, . Late rectal bleeding after conformal radiotherapy for prostate cancer: NTCP modelling. Radiother Oncol 2008;88:S332–3.
   Google Scholar
• Peeters STH, Hoogeman MS, Heemsbergen WD, Hart AAM, Koper PCM, Lebesque JV, . Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 2006;66:11–9.
   PubMed Web of Science ®Google Scholar
• Söhn M, Yan D, Liang J, Meldolesi E, Vargas C, Alber M, . Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys 2007;67: 1066–73.
   PubMed Web of Science ®Google Scholar
• Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Lee AK, . Fit of a generalized Lyman Normal tissue complication probability (NTCP) model to grade≥2 late rectal toxicity data from patients treated on protocol 94-06. Int J Radiat Oncol Biol Phys 2007;69:S8–9.
   Web of Science ®Google Scholar
• Fiorino C, Alongi F, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N, . Physics aspects of prostate tomotherapy: Planning optimization and image guidance issue. Acta Oncol 2008;47:1309–16.
   PubMed Web of Science ®Google Scholar
• Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, . Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009;74:392–8.
   PubMedGoogle Scholar
• Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F, . Evidence of limited motion of the prostate by careful emptying of the rectum as assessed by daily MVCT image-guidance with Helical Tomotherapy. Int J Radiat Oncol Biol Phys 2008;71:611–7.
   PubMed Web of Science ®Google Scholar
• Rijkhorst EJ, Lakeman A, Nijkamp J, De Bois J, van Herk M, Lebesque JV, . Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: Prostate, rectum, and bladder dose effects. Int J Radiat Oncol Biol Phys 2008;75:1254–60.
   Google Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095–101.
   PubMed Web of Science ®Google Scholar
• Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, . Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 2005;75:74–82.
   PubMed Web of Science ®Google Scholar
• Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, . Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: Results of a large multicenter observational study. Radiother Oncol 2009;93:197–202.
   PubMed Web of Science ®Google Scholar
• Koom WS, Sohn DK, Kim JY, Kim JW, Shin KH, Yoon SM, . Computed tomography-based high-dose-rate intracavitary brachytherapy for uterine cervical cancer: Preliminary demonstration of correlation between dose-volume parameters and rectal mucosal changes observed by flexible sigmoidoscopy. Int J Radiat Oncol Biol Phys 2007;68:1446–54.
   PubMedGoogle Scholar
• Georg P, Kirisits C, Goldner G, Dörr W, Hammer J, Pötzi R, . Correlation of dose volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI based brachytherapy. Radiother Oncol 2009;91:173–80.
   PubMed Web of Science ®Google Scholar
• Kim Y, Hsu ICJ, Lessard E, Kurhanewicz J, Noworolski SM, Pouliot J, . Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI. Radiother Oncol 2008;88:148–55.
   PubMedGoogle Scholar
• Martinez A, Linares LA, Wallace M, Galelae R. Phase II prospective non-randomized trial of the use of conformal high dose rate brachytherapy alone for the treatment of favorable stage adenocarcinoma of the prostate. Prostate Brachytherapy International Group. Study HDR-01, 2007.
   Google Scholar
• Roach M, Winter K, Michalski JM, Cox JD, Purdy JA, Bosch W, . Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys 2004; 60:1351–6.
   PubMedGoogle Scholar
• Nutting CM, Corbishley M, Sanchez-Nieto B, Cosgrove VP, Webb S, Dearnaley D, . Potential improvements in the therapeutic ratio of prostate cancer irradiation: Dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol 2002;75:151–61.
   PubMed Web of Science ®Google Scholar
• Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999;44:921–9.
   PubMed Web of Science ®Google Scholar
• Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, . Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: A sequential dose-escalation pilot study. Int J Radiat Oncol Phys 2009; 75:656–63.
   PubMed Web of Science ®Google Scholar
• De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, . The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005;75:325–33.
   PubMed Web of Science ®Google Scholar
• Housri N, Ondos J, Choyke PL, Barbara A, Ning H, Citrin D, . Tumor nodule location predicts the feasibility of intraprostatic high-dose irradiation in men with localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;75(Suppl1):S14–4.
   Google Scholar
• Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, . Intensity modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008;72:799–807.
   PubMed Web of Science ®Google Scholar
• Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF. Diffusion-weighted MRI of peripheral zone prostate cancer: Comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010;194:W316–22.
   PubMed Web of Science ®Google Scholar